Decibel Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Growjo Ranking



Estimated Revenue & Valuation

  • Decibel Therapeutics's estimated annual revenue is currently $14.6M per year.(i)
  • Decibel Therapeutics received $55.0M in venture funding in June 2018.
  • Decibel Therapeutics's estimated revenue per employee is $155,000
  • Decibel Therapeutics's total funding is $189.2M.
  • Decibel Therapeutics's current valuation is $116.1M. (January 2022}

Employee Data

  • Decibel Therapeutics has 94 Employees.(i)
  • Decibel Therapeutics grew their employee count by 57% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. Hearing loss is the most prevalent form of sensory impairment. It is estimated that 50 million people in the U.S., and 360 million people worldwide, suffer from some type of hearing loss. Hearing disorders affect people of all ages and can have a profound impact on quality of life. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. Founded by the world's preeminent experts in inner ear biology and hearing disorders, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and SR One and is headquartered in Boston, Mass. For more information and to browse career opportunities at Decibel Therapeutics, please visit

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Decibel Therapeutics News

2020-11-09 - Decibel Therapeutics : Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance

Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D financing, which raised $82.2M. The financing was led by OrbiMed, with new investment ...

2020-11-09 - Decibel scores $82M to push hearing loss gene therapy into the clinic W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance

Launched in 2015 to tackle hearing loss broadly, Decibel Therapeutics kicked off 2020 with a new CEO and an R&D makeover. Nine months later, it’s grabbing $82 million to propel its lead programs into and through the clinic, including a gene therapy for children with congenital deafness and a pro ...

2020-11-10 - Decibel Therapeutics lands $82M+ for hearing loss treatment

Decibel Therapeutics, a developer of treatments for hearing loss and balance disorders, has raised $82.2 million in an oversubscribed Series D. The round was led by OrbiMed, with new investors such as BlackRock Health Sciences, Janus Henderson, Casdin Capital and Surveyor Capital also joining. D ...

09/07/2019 - Frequency Plans IPO for Hearing Loss Drug & More ...

Frequency Therapeutics is developing a hearing loss drug that taps into the ... Another Boston firm, Decibel Therapeutics, is developing small ...

09/08/2019 - Biotech execs criticize 'atmosphere of intimidation' amid ...

The letter was written together by Ovid Therapeutics CEO and ... Acorda Therapeutics CEO Ron Cohen, Decibel Therapeutics CEO Steven ...

06/26/2019 - Decibel Therapeutics Appoints Healthcare Industry Veteran ...

BOSTON--(BUSINESS WIRE)-- Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Decibel Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-10-16$52.0MAThird Rock Ventures LLCArticle